Healthcare Facilities & Services
Labgenomics Co Ltd:Receives a patent on April 28, for method of detecting chromosomal abnormalities.Patent number of 10-2015-0030641.
Labgenomics Co Ltd:Receives a patent on April 6, for High Definition Probe for detecting human papilloma virus and kit using the same.Patent number of 2015-0130985.
LifeWatch AG:Announces that it has received FDA clearance for its continuous vital signs monitoring service.
LifeWatch AG:Receives FDA clearance for its Mobile Cardiac Telemetry 1-Lead Patch.
New data from CombiMatrix Corp study support follow-up diagnostic testing to confirm positive results from non-invasive prenatal testing
CombiMatrix Corp:New data from Combimatrix study support follow-up diagnostic testing to confirm positive results from non-invasive prenatal testing.Overall true positive and false positive rates for nipt versus diagnostic testing were estimated at about 70 pct. and 20 pct., respectively.Says data show significant false positive rates for microdeletions.
Quest Diagnostics Inc receives FDA clearance to add genital swab claim to moderate complexity simplexa HSV 1 & 2 direct molecular test
Quest Diagnostics Inc:Focus Diagnostics products business has received FDA 510 clearance to add genital swab claim to simplexa HSV 1 & 2 direct molecular test on the integrated cycler.
Cancer Genetics Inc:Says will provide comprehensive biomarker and genomic testing for CLL.Says CLL trials expected to contribute up to $6.2 mln in revenue over several years as patients are selected, treated, and monitored.
Psychemedics Corporation:Says addition of 2 new drugs to the company's drug testing panels.Addition of Oxymorphone was made to the synthetic opiate testing panel and D-Amphetamine/Adderall was added as an option to the Amphetamine panel.
LifeWatch AG:Lifewatch Mobile Cardiac Telemetry Patch application filed with the U.S. FDA.
Quest Diagnostics Inc:Announced LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that includes.Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs).